The MIND diet on trial: can diet choices impact cognitive health?
The results were lackluster, but a closer look leaves room for other explanations
Reassessing the relationship between alcohol intake and cardiovascular disease risk
Mendelian randomization offers clearer insights than epidemiology or randomized trials to date
“Biological” clocks: a peek into the future or a haphazard guess of mortality?
Potential uses for the epigenetics of aging and why I don’t put much stock in epigenetics-based aging clocks at present
Continuous glucose monitoring to improve health in non-diabetics
Individualizing blood glucose control and its benefits
Do GLP-1 receptor agonists improve cardiovascular health independently of weight loss?
A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that’s not the question we ought to be asking.
How does APOE status impact the relationship between obesity and dementia risk?
Obesity has been reported by some to increase risk of dementia, while other studies have reported that obesity is protective against dementia. Might the effects of APOE genotype help to explain the discrepancy?
Understanding the Relationship Between Body Composition and Mortality Using Artificial Intelligence (AI)
For predicting health outcomes, more information means more accuracy
Is the frequency of menopausal symptoms an early barometer for later-in-life brain health?
More than “bothersome”: Frequent menopausal hot flashes during sleep are associated with greater white matter hyperintensity volume
Is testosterone replacement therapy both safe and effective in men with higher cardiovascular risk factors?
An assessment of the results from the long-awaited TRAVERSE trial
Could a psoriasis drug find new purpose in treating alcohol use disorder?
Recent pilot research suggests that the psoriasis drug apremilast may have promise in curbing excessive drinking in those with alcohol use disorder.